Owners, management and financials
CVR: 38793594
Secondary names: Inphena Pharma A/S, Inphena Biotech A/S, Copenhagen Bio A/S
Previous names: Inphena ApS, Inphena A/S
DKK 23,138,320
Gross profit
Net result: DKK 1,518,132
Afyx Capital ApS (66,66-89,99%)
CVR · view owners
Claus Juan Møller-San Pedro
Board: Ole Baadsgaard (chair) and 3 members
CVR · view management
Active
Founded 12 July 2017
CVR · view overview
13 employees
CVR · 2026
Owner registered: Afyx Capital ApS
CVR · 18/06/2024
View the full event history
Afyx Therapeutics A/S is a Danish company of the type Aktieselskab based in Hørsholm, founded in 2017. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named Inphena A/S and Inphena ApS. The management consists of Claus Juan Møller-San Pedro. The board consists of Ole Baadsgaard (chair), Claus Juan Møller-San Pedro, Pia Leah Møller-San Pedro and Søren Mohrsen Kjær. The company is owned by Afyx Capital ApS. The company has 13 employees (2026). In 2025, the company reported a gross profit of DKK 23,138,320 and a net result of DKK 1,518,132 compared with DKK -3,810,585 the year before. Equity in the 2025 report amounted to DKK 36,178,254.
Source: annual report 2025, Danish Business Authority
Afyx Therapeutics A/S has shown a significant recovery in its financial health, posting a gross profit of 23,138,320 DKK in 2025, up from a loss of 3,222,038 DKK in 2022. However, the company has faced volatility, with profits fluctuating from a loss of 7,273,933 DKK in 2022 to a profit of 1,518,132 DKK in 2025. Despite the positive trajectory in recent years, the equity position improved dramatically to 36,178,254 DKK in 2025 from a negative equity of -1,031,086 DKK in 2022, indicating a strong recovery. Overall, while Afyx Therapeutics is positioned to capitalize on growth opportunities within the pharmaceutical manufacturing sector, its past losses and reliance on gross profit rather than revenue highlight ongoing concerns regarding sustainability and market competitiveness.
AI-generated summary · Generated 13/08/2026
Selskabets formål er at foretage salg og udvikling af lægemidler, behandlinger og medicinsk udstyr til brug globalt, samt andre aktiviteter der står i forbindelse hermed.
Source: annual reports filed with the Danish Business Authority.
| Period | Gross Profit | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 202501/01/2025 – 31/12/2025 | 23.1 mio. | 1.5 mio. | 40.9 mio. | 36.2 mio. | 5 | |
| 202401/01/2024 – 31/12/2024 | 23.5 mio. | -3.8 mio. | 15.5 mio. | 9.7 mio. | 11 | |
| 202301/01/2023 – 31/12/2023 | 6.4 mio. | -2.3 mio. | 15.8 mio. | 4.7 mio. | 5 | |
| 202201/01/2022 – 31/12/2022 | -3.2 mio. | -7.3 mio. | 13.4 mio. | -1 mio. | 3 | |
| 202101/01/2021 – 31/12/2021 | 1.5 mio. | -814 t. | 9.8 mio. | 6.2 mio. | 2 | |
| 202001/01/2020 – 31/12/2020 | -586 t. | -1.5 mio. | 6.1 mio. | 4.7 mio. | 2 | |
| 201901/01/2019 – 31/12/2019 | -1.1 mio. | -1.6 mio. | 2.3 mio. | 1 mio. | 1 |
Compared to 128 companies in Fremstilling af farmaceutiske præparater
Comparison is based on industry median values
Screen owners and management against the Danish FSA's official PEP lists
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningThe CVR number of Afyx Therapeutics A/S is 38793594.
Afyx Therapeutics A/S is owned by Afyx Capital ApS.
The management of Afyx Therapeutics A/S consists of Claus Juan Møller-San Pedro.
The board of Afyx Therapeutics A/S consists of Ole Baadsgaard, Claus Juan Møller-San Pedro and Pia Leah Møller-San Pedro, with Ole Baadsgaard as chair.
In 2025, Afyx Therapeutics A/S reported a gross profit of DKK 23,138,320.
Afyx Therapeutics A/S had 13 employees in 2026 according to the Danish CVR register.
Claim this page to add your logo and social links. Free to get started.
Afyx Therapeutics A/S has published its annual report for 2025. Gross profit came to DKK 23,138,320, and the net result was DKK 1,518,132.
Contact info changed: new phone: 71747174, new email: [email protected], new website: www.afyxtx.com (June 8, 2026).
Contact info changed: new phone: 71747174, new email: [email protected], new website: www.afyxtx.com (February 19, 2026).
Afyx Therapeutics A/S has published its annual report for 2024. Gross profit came to DKK 23,467,830, and the net result was DKK -3,810,585.
As of December 3, 2024, PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB has been appointed auditor of Afyx Therapeutics A/S.
As of December 3, 2024, GILFELT REVISION REGISTRERET REVISIONSANPARTSSELSKAB has stepped down as auditor of Afyx Therapeutics A/S.
As of June 18, 2024, Afyx Capital ApS is registered as an owner of Afyx Therapeutics A/S with an ownership share of 66%.
Afyx Therapeutics A/S has published its annual report for 2023. Gross profit came to DKK 6,404,980, and the net result was DKK -2,253,249.
As of April 3, 2024, Søren Mohrsen Kjær has joined the board of directors of Afyx Therapeutics A/S.
On April 3, 2024, the company changed its name from Inphena A/S to Afyx Therapeutics A/S.
As of December 21, 2023, GILFELT REVISION REGISTRERET REVISIONSANPARTSSELSKAB has been appointed auditor of Afyx Therapeutics A/S.
As of December 21, 2023, Ole Baadsgaard has joined the board of directors of Afyx Therapeutics A/S.
As of December 21, 2023, Claus Juan Møller-San Pedro has joined the board of directors of Afyx Therapeutics A/S.
As of December 21, 2023, Pia Leah Møller-San Pedro has joined the board of directors of Afyx Therapeutics A/S.
On December 21, 2023, the company changed its name from Inphena ApS to Inphena A/S.
As of December 20, 2023, Claus Juan Møller-San Pedro has left the board of directors of Afyx Therapeutics A/S.
As of September 7, 2023, Søren Anker Nielsen has left the board of directors of Afyx Therapeutics A/S.
As of September 7, 2023, Claus Juan Møller-San Pedro is registered as adm. dir. of Afyx Therapeutics A/S.
As of September 7, 2023, Søren Anker Nielsen has stepped down as adm. dir. of Afyx Therapeutics A/S.
Afyx Therapeutics A/S has published its annual report for 2022. Gross profit came to DKK -3,222,038, and the net result was DKK -7,273,933.
As of March 23, 2023, Claus Juan Møller-San Pedro has joined the board of directors of Afyx Therapeutics A/S.
As of March 23, 2023, Søren Anker Nielsen has joined the board of directors of Afyx Therapeutics A/S.
As of March 23, 2023, Richard Henry Poulsen has stepped down as director of Afyx Therapeutics A/S.
As of March 22, 2023, Søren Anker Nielsen has left the board of directors of Afyx Therapeutics A/S.
Afyx Therapeutics A/S has published its annual report for 2021. Gross profit came to DKK 1,509,144, and the net result was DKK -814,180.
As of October 7, 2021, Richard Henry Poulsen is registered as director of Afyx Therapeutics A/S.
As of October 7, 2021, Søren Anker Nielsen is registered as adm. dir. of Afyx Therapeutics A/S.
As of October 6, 2021, Richard Henry Poulsen has stepped down as adm. dir. of Afyx Therapeutics A/S.
Afyx Therapeutics A/S has published its annual report for 2020. Gross profit came to DKK -585,934, and the net result was DKK -1,506,650.
Afyx Therapeutics A/S has published its annual report for 2019. Gross profit came to DKK -1,134,301, and the net result was DKK -1,569,660.
Afyx Therapeutics A/S has published its interim report for the period July 12, 2017 – December 31, 2018.
As of August 14, 2017, Richard Henry Poulsen is registered as adm. dir. of Afyx Therapeutics A/S.
As of August 14, 2017, Søren Anker Nielsen has stepped down as adm. dir. of Afyx Therapeutics A/S.
As of July 12, 2017, Søren Anker Nielsen has joined the board of directors of Afyx Therapeutics A/S.
As of July 12, 2017, Søren Anker Nielsen is registered as adm. dir. of Afyx Therapeutics A/S.
Afyx Therapeutics A/S was founded on July 12, 2017.
Companies in the same industry and area
CVR 30082346
CVR 36494433
CVR 37509736
CVR 39161672
CVR 41489189
